These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 33038451)

  • 1. Protein kinases as targets for developing anticancer agents from marine organisms.
    Qiao G; Bi K; Liu J; Cao S; Liu M; Pešić M; Lin X
    Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129759. PubMed ID: 33038451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Protein Kinase Inhibitors with Traditional Chinese Medicine.
    Zhang Y; Liu M; Wang J; Huang J; Guo M; Zuo L; Xu B; Cao S; Lin X
    Curr Drug Targets; 2019; 20(15):1505-1516. PubMed ID: 31376819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.
    Liu Y; Wan WZ; Li Y; Zhou GL; Liu XG
    Oncotarget; 2017 Jan; 8(4):7181-7200. PubMed ID: 27769061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
    Asati V; Mahapatra DK; Bharti SK
    Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alisertib induces cell cycle arrest and autophagy and suppresses epithelial-to-mesenchymal transition involving PI3K/Akt/mTOR and sirtuin 1-mediated signaling pathways in human pancreatic cancer cells.
    Wang F; Li H; Yan XG; Zhou ZW; Yi ZG; He ZX; Pan ST; Yang YX; Wang ZZ; Zhang X; Yang T; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():575-601. PubMed ID: 25632225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
    Wu P; Hu YZ
    Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
    Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinases as therapeutic targets to develop anticancer drugs with natural alkaloids.
    Ye H; Wang L; Ma L; Ionov M; Qiao G; Huang J; Cheng L; Zhang Y; Yang X; Cao S; Lin X
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1349-1361. PubMed ID: 34856772
    [No Abstract]   [Full Text] [Related]  

  • 12. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural products targeting autophagy via the PI3K/Akt/mTOR pathway as anticancer agents.
    Sun H; Wang Z; Yakisich JS
    Anticancer Agents Med Chem; 2013 Sep; 13(7):1048-56. PubMed ID: 23293890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel cancer chemotherapy hits by molecular topology: dual Akt and Beta-catenin inhibitors.
    Zanni R; Galvez-Llompart M; Morell C; Rodríguez-Henche N; Díaz-Laviada I; Recio-Iglesias MC; Garcia-Domenech R; Galvez J
    PLoS One; 2015; 10(4):e0124244. PubMed ID: 25910265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role and Therapeutic Targeting of the PI3K/Akt/mTOR Signaling Pathway in Skin Cancer: A Review of Current Status and Future Trends on Natural and Synthetic Agents Therapy.
    Chamcheu JC; Roy T; Uddin MB; Banang-Mbeumi S; Chamcheu RN; Walker AL; Liu YY; Huang S
    Cells; 2019 Jul; 8(8):. PubMed ID: 31370278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Progress of Marine Polypeptides as Anticancer Agents.
    Zheng L; Xu Y; Lin X; Yuan Z; Liu M; Cao S; Zhang F; Linhardt RJ
    Recent Pat Anticancer Drug Discov; 2018; 13(4):445-454. PubMed ID: 29708076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity.
    Ibáñez E; Agliano A; Prior C; Nguewa P; Redrado M; González-Zubeldia I; Plano D; Palop JA; Sanmartín C; Calvo A
    Curr Med Chem; 2012; 19(18):3031-43. PubMed ID: 22455594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing the PI3K/Akt/mTor pathway using
    Phyu SM; Tseng CC; Fleming IN; Smith TA
    Sci Rep; 2016 Nov; 6():36544. PubMed ID: 27811956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [PI3K-AKT-mTOR pathway inhibitors].
    Cortot A; Armand JP; Soria JC
    Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
    Li W; Sun Q; Song L; Gao C; Liu F; Chen Y; Jiang Y
    Eur J Med Chem; 2017 Dec; 141():721-733. PubMed ID: 29107429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.